Introduction
Scatter factor (SF) (also called hepatocyte growth factor (HGF)) stimulates invasion, proliferation, differentiation, angiogenesis and tumorigenesis in different cell types under different circumstances. The actions are mediated through its receptor, the c-Met tyrosine kinase (Bottaro et al., 1991) . Although SF can stimulate apoptosis in hepatocarcinoma cells (Matteucci et al., 2003) , in most cell types and contexts, SF is cytoprotective because of to its ability to stimulate antiapoptotic signaling and enhance cell survival (Frisch and Francis, 1994; Bardelli et al., 1996) . SF was found to protect epithelial, carcinoma and glioma cells against DNA damaging agents, including adriamycin (ADR, a DNA topoisomerase IIa inhibitor), ionizing radiation, cisplatinum (a DNA cross-linking agent), and other agents (Fan et al., 1998 (Fan et al., , 2001 Bowers et al., 2000) . These findings may be significant because expression of SF and c-Met are upregulated in various tumor types (e.g., breast cancers, gliomas and bladder cancers) (Jin et al., 1997; Rosen et al., 1997) . Thus, the accumulation of SF and c-Met might contribute to chemoresistance and radioresistance of the tumors.
Studies of the mechanisms of SF protection against DNA damaging agents have identified some of the signal transduction pathway components that mediate cell protection. This pathway involves signaling through phosphatidylinositol-3-kinase (PI3K) and activation of c-Akt, a serine/threonine protein kinase (Bowers et al., 2000; Fan et al., 2000 Fan et al., , 2001 . The p21-associated kinase-1 (Pak1) acts downstream of c-Akt to promote cell survival; and nuclear factor-kappa B (NF-kB) and several of its target genes are downstream of these kinases in the SF-protection pathway (Fan et al., 2001 (Fan et al., , 2005 . In addition to these survival-promoting proteins, the multi-substrate adapter Grb2-associated binder-1 (Gab1) and the tumor suppressor phosphatase and tensin homolog (PTEN) function upstream of c-Akt to inhibit cell protection by SF (Fan et al., 2001) .
Previous studies have identified three effector signaling pathways through which oncogenic Ras signaling can stimulate tumorigenesis and other activities. These include pathways involving PI3K, Raf1 and RalGDS (Ral guanine nucleotide dissociation stimulator) (Chung et al., 1993; White et al., 1995; Yang et al., 1998; Peyssonnaux et al., 2000; McFarlin et al., 2003) . Specific mutations of the 'effector loop' of the Ras protein can preserve some interactions with effector proteins, whereas disrupting others (de Vos et al., 1988; Milburn et al., 1990) , thus enabling studies of one or another signaling pathway downstream of Ras. We have investigated the roles of Ras and several pathways downstream of Ras in mediating the ability of SF to stimulate NF-kB transcriptional activity and protection against ADR. These studies identify a stimulatory role for Raf1 and an inhibitory role for the small GTPase RalA in modulating SF-stimulated NF-kB activity and cell protection. They have also identified roles for several mitogen-activated protein (MAP) kinases in these processes.
Results

Stimulation of NF-kB signaling by Ras proteins
We tested the effects of wild-type (wt) and mutant Ras proteins on NF-kB signaling using an NF-kB-Luc reporter to measure NF-kB activity. DU-145 prostate cancer or Madin-Darby canine kidney (MDCK) epithelial cells were transfected with the indicated vectors, treated7SF (100 ng/ml Â 24 h) and harvested for luciferase assays. Typically, SF gave a 50-to 60-fold increase in NF-kB-Luc activity; and the empty pcDNA3 vector had no effect on activity. In combination with SF, an activated H-Ras codon 12 mutant (V12Ras) expression vector yielded a 6.3-to 8-fold higher NF-kB activity than SF alone (Po0.001, two-tailed t-test) ( Figure 1a ). Without SF, V12Ras gave only about 2.2-to 2.5-fold higher activity, suggesting that the effect of Ras alone is relatively modest. A farnesylation-defective mutant V12Ras that is unable to activate downstream effectors (V12S186Ras (Table 1) ) gave little or no stimulation of NF-kB activity, in the absence or presence of SF.
Effector loop mutations alter the ability of Ras to activate the Raf1 vs PI3K vs RalGDS signaling pathways and preferentially activate one pathway but not others. A mutant that activates PI3K but not Raf1 or RalGDS (V12C40Ras) gave slightly more enhancement of SF-stimulated NF-kB activity (8.3-to 9-fold) (Po0.001) than V12Ras; whereas a mutant that selectively activates RalGDS (V12G37Ras) showed reduced ability to enhance SF-induced NF-kB activity (3.9-to 4.4-fold, Po0.001) (Figure 1a ). Mutants that selectively activate Raf1 (V12S35Ras and V12E38Ras) (McFarlin et al., 2003) enhanced SF-induced NF-kB activity (Po0.001) to a somewhat lesser extent (3.9-to 6-fold) than V12Ras. All mutants gave less stimulation of NF-kB in the absence of SF (1.5-to 2.2-fold) than in its presence.
We further found that both wt-H-Ras and wt-R-Ras (the related Ras viral oncogene homolog) enhanced SF-stimulated NF-kB activity (Po0.001), by 5.5-to 5.8-fold and 3.8-to 5.2-fold, respectively (Figure 1b ). An activated R-Ras mutant (R-RasV38) gave a similar or slightly higher increase in SF-stimulated NF-kB activity (Po0.001) than wt-R-Ras. In contrast, dominant-negative (DN) H-Ras (RasN17) and R-Ras (R-RasN43) reduced SF-stimulated NF-kB activity to 18-32% of the control values (Po0.001). The stimulation of NF-kB activity by wt-H-Ras, wt-R-Ras and R-RasV38 was much smaller in the absence of SF (1.4-to 1.9-fold). RasN17 and RasN43 reduced the basal NFkB activity to about 25-50% of control (Po0.001); and the pcDNA3 and pEXV vectors did not alter NF-kB activity. Cell transfection efficiencies were D80%, similar to the efficiency numbers found in previous transient transfection studies (Fan et al., 2001 (Fan et al., , 2005 .
Ability of mutant Ras proteins to modulate cell protection by SF To test the effect of Ras proteins on cell protection, DU-145 cells were transfected with different Ras mutant vectors and then assayed for their ability to protect cells against DNA damage caused by a 2 h exposure to the ADR following treatment7SF (100 ng/ml) for 48 h. Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. In untransfected or empty vector-transfected cells ( Figure  2a and g), SF protected the cells at all ADR doses tested (Po0.001). V12C40Ras gave the largest increase in cell viability in the presence of SF (Figure 2d ), followed by V12Ras (Figure 2b ). For comparison, the dashed lines show results of empty vector transfections. Both Ras vectors also increased cell survival in the absence of SF, but the increases were smaller than those owing to SF. The farnesylation-defective mutant V12S186Ras yielded little or no changes in cell viability with or without SF (Figure 2f ), suggesting that farnesylation is required for modulation of cell survival. V12S35Ras, V12G37Ras and V12E38Ras enhanced cell survival (Figure 2c , e and h, respectively), but to a smaller degree than V12C40Ras or V12Ras. The increases in survival were larger with than without SF. Finally, the DN RasN17 abrogated cell protection (Figure 2i) , whereas wt-H-Ras enhanced protection by SF (Figure 2j ). These results are consistent with the NF-kB assays.
Raf1 enhances SF stimulation of NF-kB signaling and cell survival Activated Ras interacts with the serine/threonine kinase Raf1 and causes activation of MEK1/2 (MKK1/2) and ERK1/2 (Moodie et al., 1993; Vojtek et al., 1993) . We tested the effects of wild-type and DN Raf1 vectors on stimulation of NF-kB-Luc activity by SF. Here, wt-Raf1 enhanced SF-stimulated NF-kB-Luc activity by about fourfold (Po0.001); whereas in the absence of SF, wtRaf1 gave a smaller (o2-fold) stimulation of NF-kB activity (Figure 3a) . DN-Raf1 reduced SF-stimulated NF-kB activity by >90% (Po0.001). We performed a similar study in the presence of V12Ras, to maximally activate Ras signaling. V12Ras stimulated NF-kB-Luc activity by 2.30-to 2.5-fold in the absence of SF and enhanced the SF-stimulated NF-kB activity by 4-to 4.5-fold (Po0.001) (Figure 3b ). In contrast, DN-Raf1 reduced the SF-stimulated NF-kB activity by over 90% and it reduced (SF þ RasV12)-stimulated NF-kB activity by over 95% (Po0.001). The empty pcDNA3 vector did not affect NF-kB activity. Finally, wt-Raf1 enhanced, whereas DN-Raf1 blocked SF-stimulated cell survival (Po0.001) (Figure 3c ). The effects of wt-Raf1 on survival were smaller without SF than with SF, indicating that exogenous Raf1 enhances protection by SF. DN-Raf1 had little effect on cell survival in the absence of SF, but attenuated the SF-mediated protection, suggesting that endogenous Raf1 contributes to SF protection against ADR. Expression of the wt-Raf1 and DN-Raf1 proteins in DU-145 cells is shown in Figure 3d . These results suggest that Raf1 signaling is required for SF stimulation of NF-kB activity and protection against ADR.
RalA inhibits SF stimulation of NF-kB signaling and cell survival In NF-kB-Luc reporter assays, a wt-RalA vector reduced the basal activity and inhibited SF stimulation 2 wells were co-transfected overnight with the indicated Ras vector and NF-kB-Luc reporter using Lipofectamine (0.25 mg plasmid DNA per vector). The wells were washed, postincubated in fresh culture medium7SF (100 ng/ml) for 24 h and harvested for luciferase assays. Luciferase values are expressed relative to control cells (no vector, 0 SF) and are means7s.e.m.s of four replicate wells. The data shown are representative of at least two independent experiments. (b) Effect of additional Ras proteins on basal and SF-stimulated NF-kBLuc activity. Assays were performed exactly as described above for panel a, except using a different set of Ras vectors.
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Ras pathways modulate SF protection S Fan et al of NF-kB activity by about two-thirds (Po0.001) (Figure 4a ). Conversely, a DN-RalA-enhanced SFstimulated NF-kB activity (Po0.001), but had a modest effect on the basal NF-kB activity. RasV12 stimulated the SF-induced NF-kB activity by 3.5-to 4-fold; and wtRalA attenuated the (RasV12 þ SF)-stimulated NF-kB activity by >5-fold (Po0.001). In contrast, DN-RalA enhanced the (RasV12 þ SF)-stimulated NF-kB activity by nearly twofold (Po0.001). Without SF, the empty pcDNA3 vector and various expression vectors yielded modest or no changes in NF-kB activity. Consistent with its ability to inhibit NF-kB signaling, wt-RalA abrogated the SF protection of DU-145 cells against ADR (Figure 4b ). The expression of wt-RalA and DNRalA was confirmed by Western blotting (Figure 4c ). To test if RalA associates with the SF receptor, DU-145 cells were treated7SF for 20 min; and c-Met was immunoprecipitated (IP'd). Western blotting showed an increase of tyrosine-phosphorylated c-Met following SF treatment (Figure 4d ). In addition, RalA, Raf1 and Ras were found in the c-Met immunoprecipitations (IPs), with no obvious differences owing to SF treatment (but see below). Finally, we tested the ability of wt-RalB to modulate the SF stimulation of NF-kB activity. wt-RalB caused a reduction in SF stimulated NF-kB activity, but to a slightly lesser extent than RalA (Figure 4e ). These findings suggest that the Ral GTPases inhibit SF-mediated NF-kB signaling and cell protection.
Ability of Ras, Raf1 and RalA to modulate SF stimulation of IKK-b kinase activity NF-kB activity is inhibited by IkB proteins which maintain p65RelA within the cytoplasm. These proteins Figure 2 Effect of Ras proteins on SF protection against ADR. Proliferating DU-145 cells in six-well dishes were transfected overnight with the indicated Ras vector (5 mg of plasmid DNA per well), washed and allowed to recover for several hours. The cells were then harvested, plated into 96-well dishes, allowed to attach overnight, incubated7SF (100 ng/ml Â 48 h), exposed to different doses of ADR (2 h at 371C) and postincubated for 48 h in fresh drug-free medium. The cells were then analysed for cell viability using MTT assays. Cell viability values are expressed relative to non-ADR-treated control cells and represent means7s.e.m.s of 10-replicate wells. The results shown are representative of at least two independent experiments. The Ras vectors tested were: empty pcDNA3 vector (a), V12Ras (b), V12S35Ras (c), V12C40Ras (d), V12G37Ras (e), V12S186Ras (f), empty pSVE vector (g), V12E38Ras (h), RasN17 (i) and wt-H-Ras (j). The dashed lines represent empty vector-transfected cells.
(IkB-a and IkB-b) are regulated by serine phosphorylations, which mark them for ubiquitin-mediated degradation. A key mediator of IkB phosphorylation is the IkB kinase (IKK) complex (Woronicz et al., 1997; Hu and Wang, 1998; May et al., 2000) , which contains IKK-a, IKK-b and IKK-g (NEMO). One measure of IKK activation is phosphorylation on serine of the IKK-a/b proteins. First, we tested the effect of SF and V12Ras on IkB-a degradation. In both DU-145 and MDCK cells, SF treatment for 20 min caused a large reduction of IkB-a protein; whereas V12Ras alone caused only a modest reduction of IkB-a protein ( Figure 5a ). The combination (V12Ras þ SF) caused loss of detectable IkB-a protein, suggesting that V12Ras enhances the ability of SF to induce IkB-a degradation.
To test the effect of Ras mutants on IKK phosphorylation, DU-145 cells were transfected with different Ras vectors, treated with SF for 20 min, and Western blotted for phosphorylated and total IKK proteins. Each mutant Ras protein was expressed ( Figure 5b ). SF increased the phosphorylation on IKK-a/b; and with SF present, V12Ras and the effector loop mutants (but not the farnesylation-defective mutant V12S186Ras) further enhanced the phosphorylation of IKK-a/b, compared We tested the effect of Ras, Raf1 and RalA proteins on IKK-b kinase activity in DU-145 cells using an assay kit that measures the ability of the sample to phosphorylate a biotinylated IkB-a substrate peptide (see Materials and methods). Here, SF-stimulated kinase activity by about fivefold; and the activated Ras proteins V12Ras, V12C40Ras, V12S35Ras, V12G37Ras and V12E38Ras-enhanced SF-stimulated kinase activity (Po0.001) by five-to sevenfold (Figure 5d ). V12S186Ras and the empty pcDNA3 vector did not alter IKK activity. In the absence of SF, the active RasV12 mutants showed modest (p1.6-fold) stimulation of IKK-b kinase activity. wt-R-Ras, the activated mutant R-RasV38 and wt-H-Ras-enhanced SF-stimulated IKK-b activity by five-to sixfold (Po0.001) ( Figure 5e ). In contrast, the DN R-RasN43 and RasN17 proteins blocked SF-stimulated IKK-b activity (Po0.001), suggesting that endogenous Ras contributes to SF stimulation of IKK-b activity.
In further studies, wt-Raf1 enhanced the SF-stimulated IKK-b kinase activity by 4.8-fold (Po0.001); but it had a modest effect on the kinase activity in the absence of SF (about twofold stimulation) (Figure 5f ). In contrast, DN-Raf1 abrogated SF stimulation of IKK-b kinase activity (Po0.001). Finally, wt-RalA inhibited the SF-stimulated kinase activity (Po0.001); whereas DN-RalA enhanced SF-stimulated kinase activity by another fourfold (Po0.001) (Figure 5g ). These findings suggest that Ras and Raf1 positively regulate, whereas RalA negatively regulates the ability of SF to stimulate IKK-b kinase activity. Thus, the results of the IKK-b activity assays correlated well with the NF-kB-transcriptional assays.
Role of MAP kinases in SF stimulation of NF-kB activity
We tested the role of various MAP kinase pathways in the SF stimulation of NF-kB activity, using expression vectors for wt, constitutively active (ca) and DN MAP kinase kinase proteins. MKK1 and MKK2 activate the classic extracellular signal-regulated kinases (ERK1 and ERK2) (Zheng and Guan, 1993) . Neither wt-MKK1 nor DN-MKK1 nor wt-MKK2 nor DN-MKK2 had any significant effect on NF-kB-Luc activity in DU-145 cells without or with SF present, even though the proteins were well expressed (data not shown).
MKK4 is a dual-specificity kinase that activates the stress-activated kinases c-jun NH2-terminal kinase and p38 (Hog1), but not ERK1/2 and is unresponsive to Raf1 (Lin et al., 1995) . wt-MKK4 caused a modest increase in SF-stimulated NF-kB activity (D20%); whereas DN-MKK4 caused a modest decrease in activity (D20%) (data not shown). MKK5 is an upstream activator of ERK5 (MAPK7) (Mody et al., 2003) . Neither wt-MKK5 nor DN-MKK5 altered the basal or SF-stimulated NF-kB activity (data not shown).
In contrast, MKK3 and MKK6 (both of which activate p38 (Derijard et al., 1995; Wang et al., 1997) ) strongly regulated NF-kB activity (Figure 6a and b) . The wt and ca mutant MKK3 and MKK6 proteins stimulated basal NF-kB-Luc activity by about three-to fourfold (Po0.001) and enhanced the SF-stimulated NF-kB-Luc activity by 3.5-to 5-fold (Po0.001). Conversely, DN-MKK3 and DN-MKK6 reduced SFstimulated NF-kB activity (Po0.001) to about 15% of control. A selective inhibitor of p38 kinase activity, SB202190 (10 mM), reduced SF-stimulated NF-kB activity by 50-70% and abrogated the ability of MKK3 and MKK6 to stimulate NF-kB activity in the presence or absence of SF (Figure 6c and d) . To confirm a role for the endogenous MKK3 and MKK6 proteins in NF-kB signaling, DU-145 cells were treated with MKK3 small interfering RNA (siRNA), MKK6-siRNA or controlsiRNA (50 nM Â 48 h) before testing for SF-stimulated NF-kB activity. The MKK3 and MKK6 siRNAs reduced the SF-stimulated NF-kB-Luc activity to D30-40% of that of cells treated with control-siRNA or no siRNA (Po0.01) (Figure 6e ). These findings suggest that in DU-145 cells, NF-kB activity is regulated by an MKK3/6-p38 pathway, but not by the Raf1-MEK1/2-ERK1/2 pathway.
We tested the role of p38 in mediating the enhanced SF-stimulated IKK-b kinase activity because of V12Ras in DU-145 cells, using the p38 inhibitor SB202190. Here, we used a higher concentration of SB202190 (50 mM) than in the NF-kB-Luc assay (10 mM), to ensure maximal inhibition of p38. As before, SF caused a fivefold increase in IKK-b activity; and (SF þ V12Ras) caused another fivefold increase beyond that owing to SF alone or (SF þ pcDNA3) (Figure 6f ). SB202190 abrogated the increase in IKK-b activity owing to SF alone and the further increase in IKK-b activity owing to V12Ras. Thus, IKK-b activity for (SF þ V12 RalA interacts with c-Met receptor in a SF-independent manner. DU-145 cells in 100 mm dishes were incubated in serum-free medium7SF (100 ng/ml) for 20 min; and whole-cell lysates were subjected to IP using an anti-c-Met antibody (see Materials and methods section). Precipitated proteins were analysed by SDS-PAGE and blotted using antibodies for total c-Met, phospho-c-Met (tyrosine-1349), RalA, Raf1 and Ras. (e) Effect of RalB on SF stimulation of NF-kB-Luc activity. Assays were performed as described for panel a, except that a wild-type RalB expression vector was used instead of RalA.
Ras þ SB202190) was slightly less than that for SF alone. The ability of the siRNAs to knock down MKK3 and MKK6 proteins is shown in Figure 6g . These findings suggest that the ability of V12Ras to enhance the SF-stimulated IKK-b activity in DU-145 cells is dependent upon p38.
Ras mutants stimulate c-Akt activity
We showed that c-Akt signaling is required for SF stimulation of NF-kB activity and protection against ADR (Fan et al., 2001 (Fan et al., , 2005 ). Here, we tested the ability of Ras mutant proteins to activate c-Akt, indicated by phosphorylation on serine-473 and threonine-309. A 20 min exposure to SF-stimulated Akt phosphorylation on both residues in empty vector-transfected cells (Figure 7a ). V12Ras and all V12Ras effector loop mutants (but not the farnesylation-defective mutant V12S186Ras) enhanced Akt phosphorylation in SFstimulated cells; whereas there were no significant changes in total Akt or actin protein. V12Ras and the effector loop mutants (but not V12S186Ras) also induced Akt phosphorylation in the absence of SF (Figure 7b ). There were no consistently observed differences among these mutants (except V12S186Ras) in the ability to activate Akt.
Thus, V12Ras mutant proteins that selectively activate three effector pathways (PI3K, Raf1 or RalGDS) each enhanced SF-stimulated Akt phosphorylation, IKK-b kinase activity, NF-kB activity and cell survival. The finding that a Ras mutant that selectively activates RalGDS (V12G37Ras) has these activities was surprising, because RalA and RalB, two major targets of RalGDS, inhibited the same SF-stimulated activities. We tested our Ras effector loop mutants to confirm that they behave as expected. DU-145 cells were transfected with different mutants or with V12Ras itself and tested for association of the Ras proteins with p110a (catalytic subunit of PI3K), Raf1 and RalGDS. For this purpose, we constructed FLAG-tagged Ras mutant expression vectors to facilitate IP of the Ras proteins. By IPWestern blotting, V12Ras associated with all three effector proteins; whereas V12C40Ras associated only with p110a. V12S35Ras and V12E38Ras interacted only with Raf1; and V12G37Ras interacted only with RalGDS (Figure 7c) . Thus, the mutant Ras proteins behave as expected.
Finally, we studied the role of c-Akt in regulating the ability of V12Ras to enhance SF-stimulated NF-kB activity. In the absence of V12Ras, a kinase-dead DN-Akt vector blocked the SF-stimulated NF-kB (Figure 8d ). Finally, we tested the effects of Raf1 or RalA on IKK-b kinase activity in cells treated with (SF þ V12Ras). SF alone gave a fivefold increase in kinase activity and (SF þ V12Ras) gave a further fivefold increase beyond that of SF alone ( Figure 8e ). DN-Raf1 abrogated the increased IKK-b kinase activity owing to (SF þ V12Ras); whereas wtRalA reduced the kinase activity in the presence of (SF þ V12Ras) to 55% of that found in the absence of wt-RalA (Po0.001). The ability of the siRNAs to knock down Raf1 and RalA protein is shown in Figure 8f . Thus, DN-Raf1 was more effective than wt-RalA in modulating the stimulatory effect of the combination of (SF þ V12Ras).
Raf1 and IKK phosphorylation in the c-Met complex
We tested the effect of SF and V12Ras on the phosphorylation (a measure of activation) of Raf1. DU-145 cells were transfected with V12Ras vs pcDNA3 vector; treated7SF (20 min) and subjected to IPWestern blotting using an antiRaf1 antibody. The total levels of Raf1 and c-Met protein associated with Raf1 were unaffected by these treatments; but the phosphorylated c-Met associated with Raf1 was increased in V12Ras-transfected cells compared to pcDNA3-transfected cells (Figure 9a ). SF increased the phospho-Raf1 (serine-43) levels in both pcDNA3 and V12Ras-transfected cells; but the SF-induced increase in phosphoRaf1 was greater in V12Ras-transfected cells. V12Ras Figure 1a legend. (e) PTEN blocks (SF þ V12Ras)-mediated stimulation of NF-kB activity. Assays were performed as described in Figure 1a legend.
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had little effect on Raf1 phosphorylation without SF; but with SF present, V12Ras increased the amount of phospho-Met associated with Raf1. In a similar experiment using an anti-c-Met antibody for IP, SF increased the levels of phospho-Met; and V12Ras further enhanced SF-induced c-Met phosphorylation (Figure 9b ). There were no changes in the total Raf1, but there was more phospho-Raf1 associated with c-Met in cells treated with (SF þ V12Ras) as compared with (SF þ pcDNA3) (Figure 9b ). These findings suggest that activated c-Met may mediate SF-induced Raf1 phosphorylation and that V12Ras enhances SF-induced Raf1 phosphorylation in the signaling complex. In the same experiments, RalA associated with both Raf1 and c-Met, in a SF-and V12Ras-independent manner. IKK-a and IKK-b also associated with Raf1 and c-Met. Phospho-IKK-a/b associated with Raf1 and c-Met in a SF-and V12Ras-dependent manner: SF increased the amount of phospho-IKK-a/b in Raf1 and c-Met IPs; whereas V12Ras further increased the phospho-IKK-a/b levels in these IPs in SF-treated cells. Finally, we tested the effect of Raf1-siRNA (Figure 9c ) or RalA-siRNA (Figure 9d ) on the ability of SF to induce IKK-a/b phosphorylation. As expected, SF stimulated IKK-a/b phosphorylation, but did not significantly alter total IKK-a, IKK-b or actin levels. Knock down of Raf1 blocked the SF-induced IKK-a/b phosphorylation; whereas knock down of RalA enhanced the SF-stimulated phosphorylation. These findings suggest that endogenous Raf1 and RalA, each of which associates with c-Met, modulate the ability of SF to induce IKK-a/b phosphorylation. 
V12Ras enhances SF-induced p65 nuclear translocation and NF-kB target gene expression We had shown that SF causes rapid translocation of the p65 subunit of NF-kB from cytoplasm to nucleus (Fan et al., 2005 ). Here, we tested the effect of V12Ras on nuclear translocation of p65 after a brief (20 min) exposure to SF, by immunofluorescence microscopy. In basal conditions, cells transfected with V12Ras or pcDNA3 vector showed a predominantly cytoplasmic distribution of p65 (Figure 10a ). In response to SF, p65 become mostly localized in the nucleus. Consistent with the ability of V12Ras to stimulate NF-kB Ras pathways modulate SF protection S Fan et al transcriptional activity, V12Ras-transfected cells showed higher levels of immunoreactive p65 in the nucleus than pcDNA3-transfected cells. The ability of SF to cause 'scattering' (cell dispersion and a fibroblastic appearance) of DU-145 cells is illustrated in the phase contrast micrographs in Figure 10a . We have also shown that SF stimulates the expression of several known NF-kB target genes (cIAP1, cIAP2 and TRAF2) in an NFkB-dependent manner (Fan et al., 2005) . Here, we tested whether V12Ras could enhance the expression of several of these genes in SF-treated cells. The ability of SF to induce increased protein levels of cIAP2 and TRAF2 was greater in V12Ras-transfected cells than in pcDNA3-transfected cells ( Figure 10b ). As expected, the total Ras levels were significantly greater in the V12Ras-transfected cells. In contrast, there were no differences in the levels of c-Met or actin. These findings are consistent with the above studies showing that V12Ras enhances the SF-stimulated NF-kB transcriptional activity.
Discussion
These studies identify a role for p21Ras and several of its downstream effectors (Raf1 and RalA) in modulating the ability of SF to stimulate IKK-b kinase activity, NF-kB transcriptional activity and protection against ADR-induced DNA damage. In particular, Ras and Raf1 signaling enhanced SF stimulation of IKK-b activity, NF-kB activity and cell protection, whereas the RalA inhibited these activities. The ability of activated Ras (RasV12) to enhance SF-stimulated NF-kB signaling was dependent upon signaling downstream of c-Akt and Raf1; and it was negatively regulated by RalA. In addition, SF-stimulated NF-kB signaling was dependent upon endogenous Ras, Raf1 and c-Akt and was negatively regulated by endogenous RalA. Finally, although Raf1 was required for SF-stimulated NF-kB activation (and cell protection), the Raf1-MEK1/2-ERK1/2 pathway was dispensable. We do not yet know the mechanism through which Raf1 mediates the Ras pathways modulate SF protection S Fan et al activation of IKK-b and NF-kB. However, in a different context, it was observed that Raf1 can stimulate IKK-b activity by a mechanism that involves the kinase MEKK1 (MAP3K1), but is independent of the ERK1/ 2 pathway (Baumann et al., 2000) . Consistent with the ability of Ras to enhance SFstimulated IKK-b kinase and NF-kB activity, the activated mutant V12Ras also enhanced the nuclear translocation of the p65RelA subunit of NF-kB caused by SF as well as the SF-induced increases in the expression of two known NF-kB target genes, cIAP2 and TRAF2. Previously, we showed that SF induces expression of these genes in an NF-kB-dependent manner and that they contribute to the SF-mediated protection against ADR (Fan et al., 2005) .
The V12C40Ras mutant, which selectively binds p110a (Rodriguez-Viciana et al., 1997) was slightly more active than V12Ras in enhancing the SF-stimulated IKK-b kinase activity, NF-kB activity and protection against ADR. This finding is consistent with our previous studies indicating a role for PI3K/c-Akt signaling in SF-mediated cell protection (Bowers et al., 2000; Fan et al., 2000 Fan et al., , 2001 Fan et al., , 2005 , and it suggests that Ras acts, in part, upstream of PI3K in the cell protection pathway. The increased activity of V12C40Ras relative to V12Ras is consistent with an inhibitory component of Ras signaling owing to another pathway downstream of Ras (e.g., RalA) that is active in V12Ras but not in V12C40Ras. Alternatively, the V12C40Ras pathway may sequester signaling proteins from another SF signaling pathway that negatively regulates cell protection (Fan et al., 2001) .
Two Ras effector mutants that selectively bind Raf1 (V12S35 Ras and V12E38Ras) enhanced SF-stimulated IKK-b activity, NF-kB activity and cell survival. These findings, coupled to the finding that wtRaf1 enhanced the kinase, NF-kB and survival-stimulating activity of SF, suggest that Ras/Raf1 signaling contributes to these activities. The ability of DN-Raf1 or Raf1-siRNA to these activities suggests that Raf1 is required for the SF survival pathway in the cell types studied. And the ability of DN-Raf1 to block (SF þ V12Ras)-stimulated NF-kB activity is consistent with the idea that Raf1 acts downstream of Ras in this pathway. Although Raf1 contributes to SF-stimulated NF-kB activity, neither wtMEK1/2 nor DN-MEK1/2 mutants altered the SFstimulated NF-kB activity, suggesting that the ability of Raf1 to enhance the SF-stimulated NF-kB activity is not owing to the Raf1/MEK/ERK pathway. In contrast, the ability of DN-Raf1 to block and wt-Raf1 to enhance SF-stimulated IKK-b kinase activity suggest that Raf1 targets the IKK complex or a kinase upstream of IKK.
Our previous studies indicate that c-Akt signaling is required for SF-mediated NF-kB activation and cell protection (Bowers et al., 2000; Fan et al., 2000 Fan et al., , 2001 Fan et al., , 2005 . The present study revealed that DN-Akt also blocks the ability of RasV12 to enhance the SFstimulated NF-kB activity, suggesting that both Raf1 and c-Akt act downstream of Ras in the SF survival pathway. The findings are consistent with a model in which Raf1 and c-Akt act in a direct pathway leading to NF-kB activation, although these proteins are not known to participate in the same phosphorylation cascade. Alternatively, they also support a model in which Raf1 and c-Akt signaling impinge on the NF-kB pathway (e.g., at the level of IKK, a kinase upstream of IKK, and/or NF-kB itself) to synergistically activate this pathway. Here, inactivation of either Raf1 or c-Akt is sufficient to block SF-induced NF-kB activation and cell survival. The finding that wtRaf1 enhances SF-stimulated IKK-b activity and NF-kB activity by three-to fivefold is consistent with this model, because it shows that the pathway through which Raf1 stimulates SF-inducible NF-kB activity can be further activated. Similarly, we previously reported that exogenous c-Akt enhances SF-stimulated NF-kB activity by 2.5-to 3-fold, suggesting that the pathway through which endogenous c-Akt enhances SF-stimulated NF-kB activity is not maximally activated and can be further stimulated. V12G37Ras, a mutant that selectively activates the guanine nucleotide dissociation stimulator RalGDS (Albright et al., 1993; Hofer et al., 1994) , enhanced SF-stimulated IKK-b activity and NF-kB activity, but to a lesser extent than V12Ras. Studies utilizing DNRalA and RalA-siRNA suggest that RalA negatively regulates SF stimulation of IKK-b and NF-kB activity and SF protection against ADR and inhibits V12Ras-mediated enhancement of the SF stimulation of IKK-b and NF-kB activity. Our findings suggest that the endogenous protein RalA inhibits the SF survival pathway at the level of the IKK complex and NF-kB transcriptional activity. In addition, RalB, another target of RalGDS, inhibited the SF-stimulated NF-kB activity. We verified that all Ras effector loop mutant proteins tested were expressed and behaved as expected (e.g., V12G37Ras interacted with RalGDS but not p110a or Raf1). The finding that V12G37Ras enhances SF-mediated NF-kB survival signaling deserves comment, as two major targets of RalGDS, the RalA and RalB GTPases, blocked SF-stimulated NF-kB signaling.
Two possible explanations are that: (1) the V12G37Ras/RalGDS pathway activates other downstream components besides RalA and RalB; or (2) V12G37Ras (and other Ras effector mutants) activate an NF-kB stimulatory pathway independent of RalGDS, Raf1 and p110a/PI3K. Possibility (2) is consistent with the finding that each V12Ras effector mutant enhanced the SFstimulated c-Akt phosphorylation and caused c-Akt phosphorylation in the absence of SF. The finding that a farnesylation-defective mutant (V12S186Ras) did not stimulate IKK-b activity, NF-kB activity or cell protection suggests that this alternative NF-kB stimulatory pathway requires farnesylation of the Ras protein.
Ras can stimulate other effectors than p110a, Raf1 and RalGDS, including RIN1, AF6, NORE1, PLC-e and other RalGDS family members (RGL, RLF and RGL2) (Shao et al., 1999; Herrmann, 2003; Wohlgemuth et al., 2005) . Whether these or other potential Ras effectors contribute to regulation of NF-kB signaling downstream of Ras remains to be discovered.
A role for RalA in an NF-kB-survival pathway is novel, as the role of RalA in cell survival or apoptosis is not well characterized. The pathways downstream of RalA that mediate inhibition of NF-kB signaling and cell protection by SF remain to be identified. RalA signaling is not understood in great depth, but one target of RalA is phospholipase D1 (PLD1), a protein implicated in vesicle trafficking (Luo et al., 1998) . Emerging evidence suggests that the exocyst, a protein complex involved in the interaction of secretory vesicles with the plasma membrane, is a target for activated RalA and that RalA stimulates exocytosis (Camonis and White, 2005) . PLD1 may contribute to RalAmediated exocytosis (Vitale et al., 2005) . Whether PLD1 or exocyst proteins also participate in the regulation of NF-kB signaling is conjectural at this time. RalBP1 Ras pathways modulate SF protection S Fan et al (RLIP76) is a RalA-interacting protein implicated in the transport of glutathione conjugates and in mediating drug resistance (Cantor et al., 1995; Stuckler et al., 2005) , but the role of RalA in these processes is unclear.
Although MAP kinase kinases 1-5 had little or no effect on NF-kB signaling, we found that DN-MKK3 and DN-MKK6 inhibited SF stimulation of NF-kB activity and wild-type or active mutant MKK3 and MKK6 enhanced SF-stimulated NF-kB activity. Knock down of MKKs 3 or 6 blocked SF-induced NF-kB activity, suggesting roles for endogenous MKK3/6 in SF-mediated NF-kB signaling, although we did not tested whether these kinases contribute to cell survival. The stress-activated kinase p38 is a substrate for MKK3 and MKK6; and several studies suggest that p38 can stimulate NF-kB signaling (Nick et al., 1999; Shuto et al., 2001; Costantini et al., 2005) . Here, we found that a selective inhibitor of p38 (SB202190) inhibited SF-, MKK3/6-and (SF þ V12Ras)-stimulated NF-kB activity, suggesting that an MKK3/6-p38 pathway contributes to SF-stimulated NF-kB activity. Interestingly, in addition to regulating IKK-b kinase activity (demonstrated herein), p38 has been reported to mediate the phosphorylation and activation the p65RelA subunit of NF-kB in another context, whether directly or indirectly (Rahman et al., 2004) .
Using IP-Western blotting, we showed that Ras, Raf1, RalA, IKK-a and IKK-b each associated with the liganded or unliganded c-Met receptor. We further demonstrated an association of c-Met, RalA, IKK-a and IKK-b with Raf1. Within these signaling complexes, SF induced and V12Ras further enhanced the phosphorylation (activation) of Raf1 and IKK-a/b. In studies using siRNAs to knock down endogenous protein levels, we found that Raf1 is required for the SF-induced phosphorylation of IKK-a/b and that endogenous RalA suppresses IKK-a/b phosphorylation. Taken together, these findings suggest a physiological connection between Raf1, RalA and the IKK complex that can modulate the activation of IKK-a/b and NF-kB signaling. Although we did not test the activation state of the Ras and RalA GTPases, it was previously demonstrated that ligation of c-Met is required for Ras activation (conversion to the GTP-bound state) (Graziani et al., 1993) ; and it is, thus, likely that c-Met ligation is also required for RalA activation within the signaling complex. Whether c-Met can transmit a survival signal in the absence of SF is unclear; but it is interesting that the multisubstrate docking site of the c-Met receptor ( 1349 YVHVxxxYVNV) -which mediates the association of c-Met with multiple signaling proteins (e.g., Grb2, Shc, Gab1 and p110) and is required for much of its signaling activity -is not required for transduction of a Ras signal or cell scattering (Tulasne et al., 1999) . It was suggested that GDP-bound Ras may have a role in signal transduction (Stewart and Guan, 2000) . These unconventional receptor-dependent Ras signaling mechanisms are poorly understood.
Interestingly, although the Ras/Raf1 signaling pathways stimulate IKK-b activity, NF-kB activity and cell survival both in the presence and absence of SF, and to mediate cell protection in carcinoma and epithelial cell lines, the stimulatory effects of Ras and Raf1 are significantly greater in the presence of SF than in its absence. These findings suggest the possibility that the SF and Ras/Raf1 are acting through parallel pathways that interact (cross-talk) with each other. SF may activate more steps than Ras/Raf1, accounting for the greater effects of SF alone than of Ras/Raf1 alone.
Materials and methods
Cell lines and culture DU-145 human prostate cancer cells and MDCK epithelial cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum, non-essential amino acids (100 mM), L-glutamine (5 mM), streptomycin (100 mg/ml) and penicillin (100 U/ml) (all purchased from BioWhittaker, Walkersville, MD, USA). The cells were grown at 371C in a humidified atmosphere of 95% air and 5% CO 2 and were subcultured weekly, using trypsin.
Reagents
Recombinant human two-chain SF was a gift from Dr Ralph Schwall, Department of Endocrine Research, Genentech Inc. (South San Francisco, CA, USA). ADR (doxorubicin hydrochloride) and MTT were obtained from the Sigma Chemical Co. (St Louis, MO, USA). The p38 inhibitor SB202190 was purchased from CalBiochem (La Jolla, CA, USA). The antibodies used in this study are described below.
Expression vectors
The expression vectors utilized in this study are described in Table 1 .
Transient transfections
Subconfluent proliferating cells were transfected overnight with the vector of interest or with the empty pcDNA3 vector (Invitrogen, Carlsbad, CA, USA) (15 mg of plasmid DNA per 100 mm dish or 5 mg per well in six-well dishes) using Lipofectamine (Life Technologies, Gaithersburg, MD, USA) and washed to remove the excess vector and Lipofectamine. To determine the transfection efficiency, cultures were cotransfected with plasmid pRSV-b-gal (Promega Corporation, Madison, WI, USA) to allow staining with 5-bromo-4-choloro-3indolyl-b-D-galactoside reagent and visualization of transfected (blue-staining) cells.
siRNA treatments
Validated siRNAs for human Raf1 (ID no. 42858), RalA (ID no. 120429) and a negative control siRNA were purchased from Ambion (Austin, TX, USA) (see Ambion siRNA catalog for details). MKK3-siRNA (catalog no. PA-11386) and MKK6-siRNA (catalog no. PA-11388) were purchased from Dharmacon Inc. (Lafayette, CO, USA). For siRNA transfections, proliferating cells at about 30-50% of confluence were treated with the indicated siRNA using OligofectAMINE (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions. Cells were treated with 50 nM of siRNA for 48 h; and the efficacy of the siRNA treatment was verified by Western blotting.
Measurement of NF-kB transcriptional activity NF-kB activity was measured as described earlier (Fan et al., 2005) . The NF-kB-Luc reporter plasmid (NF-kB-Luc) (Stratagene, La Jolla, CA, USA) is composed of five copies of the NF-kB enhancer element upstream of a TATA box and the luciferase gene. Briefly, subconfluent proliferating cells in 2 cm 2 wells were transfected overnight with 0.25 mg of NF-kBLuc reporter and 0.25 mg of each indicated vector, using Lipofectamine. The cells were then washed to remove Lipofectamine and excess vectors, allowed to recover for several hours, treated7SF (100 ng/ml) for 24 h and harvested for measurement of luciferase activity, using the Dual Luciferase Reporter Assay System (Promega, Piscataway, NJ, USA). Transfection efficiency was determined using the Galacto-Star Mammalian Reporter Gene Assay System (Applied Biosystems, Foster City, CA, USA). Luciferase values were means7s.e.m.s of quadruplicate wells. Each experiment was performed at least twice to assure that the findings were reproducible.
ADR treatment
Subconfluent proliferating cells in six-well dishes were transfected overnight with the indicated vector(s) (5 mg of plasmid DNA per well), washed and allowed to recover for several hours in fresh culture medium. The cells were then harvested, inoculated into 96-well dishes in complete culture medium, allowed to attach overnight, washed, incubated7SF (100 ng/ml Â 48 h) in serum-free medium, exposed to different doses of ADR (2 h at 371C) and postincubated for 48 h in fresh drug-free complete culture medium (7SF). The cells were then analysed for cell viability using MTT assays. For each assay condition, cell viability was determined in 10 replicate wells. At least two independent experiments were performed for each vector tested.
MTT cell viability assay
This assay is based on the ability of viable mitochondria to convert MTT, a soluble tetrazolium salt, into an insoluble formazan precipitate, which is dissolved in dimethylsulfoxide and quantitated by spectrophotometry (Alley et al., 1988) . After ADR treatment, cells in 96-well dishes were tested for MTT dye conversion. The cell viability was calculated as the amount of MTT dye conversion relative to sham-treated control cells.
Measurement of IKK-b kinase activity
After cell transfections and SF treatment of DU-145 cells as described in the figure legends, IKK-b kinase activity was measured using the HTScan IKK-b Kinase Assay Kit (Cell Signaling Technology Inc., Danvers, MA, USA). This assay measures the ability of the cell lysate being tested to phosphorylate a biotinylated IkB-a (Ser32) substrate peptide. A phospho-IkB-a (Ser32/36)-specific mouse monoclonal antibody is used to detect the phosphorylated form of the substrate peptide. As a positive control and for standardization of the assay, the kit provides an active IKK-b kinase in the form of a glutathione S-transferase fusion protein. Each experimental condition was tested in five replicate wells, and the values of IKK-b kinase activity were expressed relative to the untransfected, nonSF treated control. Each experiment was performed at least twice to assure reproducibility of the results.
Immunoprecipitation
Ras IP To facilitate this experiment, the V12Ras, V12C40Ras, V12S35Ras, V12G37Ras and V12E38 Ras cDNAs were cloned into the pCMV-Tag2B mammalian expression vector (Invitrogen) (to allow expression of the protein with an N-terminal FLAG epitope tag) using the BamH1 and XhoI cloning sites and sequenced. DU-145 cells were transfected overnight with the different FLAG-Ras vectors (10 mg plasmid DNA per 100 mm dish), washed and postincubated for 24 h to allow gene expression. The cells were then harvested by scraping; and total cell lysates were prepared in Tris-buffered saline (TBS) buffer (20 mM Tris-HCl pH 7.5, 137 mM NaCl and 0.5% NP-40) containing Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN, USA). The lysates were passed through a 22 G needle to shear the DNA and centrifuged at 100 000 g at 41C for 30 min. The supernatant protein was quantified; and aliquots of protein (700 mg) were incubated with anti-FLAG monoclonal M2 (2.5 mg) agarose beads (Sigma, St Louis, MO, USA) at 41C for 4 h. A control IP was performed using the same quantity of nonimmune mouse IgG (catalog no. 7056, Cell Signaling Technology). The beads were then washed three times with TBS buffer. The precipitated proteins were solubilized in 2% sodium dodecyl sulfate (SDS) buffer at 451C for 1 h and analysed by Western blotting.
Raf1 and c-Met Ips Following transfection with V12Ras or empty pcDNA3 vector and treatment with SF (as described in the figure legends), DU-145 cells were scraped into 1 ml of lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 1% NP-40 and protease inhibitor cocktail set I (Calbiochem, San Diego, CA, USA)) per 100 mm dish. The lysed cells were incubated for 30 min at 01C, centrifuged at 17 000g for 15 min at 41C, and the supernatants were collected and protein concentrations determined with the Bio-Rad protein assay, using bovine serum albumin (BSA) as a standard. The IP antibodies were as follows: anti-Raf1 rabbit polyclonal antibody (Ab32025) or anti-c-Met rabbit polyclonal antibody (Ab14570) from Abcam (Cambridge, MA, USA). For IPs, 500 mg of protein was pre-cleared for 1 h by addition of BioMag beads (Qiagen, Valencia, CA, USA). The pre-cleared lysates were incubated with IP antibody (5 mg) plus Bio-Mag beads at 41C overnight. The beads were washed four times with 0.5 ml of lysis buffer; and 1 Â loading buffer (25 mM TrisHCl (pH 6.5), 5% glycerol, 1% SDS, 1% 2-mercaptoethanol and 0.05% bromphenol blue) was added. The samples were boiled for 3 min, analysed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE)); and Western blotted as described below.
Western blotting
For straight Western blotting, cells were collected using trypsin, washed twice with phosphate-buffered saline (PBS) and pelleted by centrifugation. The pellet was resuspended in radioimmunoprecipitation assay buffer (1 Â PBS, 1% NP-40, 0.5% sodium desoxycholate and 0.1% SDS), placed on ice for 30 min and spun for 15 min at 14 000 r.p.m. at 41C to remove the insoluble material. Western blotting was performed as described earlier (Fan et al., 2005) . Briefly, aliquots of whole cell protein (50 mg per lane) or IP'd proteins (see above) were electrophoresed in 4-20% SDS-polyacrylamide gradient gels and transferred to nitrocellulose membranes. The membranes were blotted using the primary antibodies listed below and then blotted with the appropriate secondary antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA, 1:1000 dilution). The blotted proteins were visualized using the enhanced chemiluminescence system (Amersham Pharmacia Biotech, Piscataway, NY, USA), with colored markers (Bio-Rad Laboratoriess, Hercules, CA, USA) as molecular size standards.
The primary antibodies were: phospho-Akt (serine-473) (np. 9271S, Cell Signaling Technology Inc., Beverly, MA, USA; 1:500); phospho-Akt (threonine-309) (monoclonal 244F9, Cell Signaling Technology); total Akt (no. 9271, Cell Signaling Technology, 1:500); c-Met (H-190, Santa Cruz, 1:1000); phospho-c-Met (tyrosine-1349) (Biosource International, Camarillo, CA, USA); FLAG (rabbit anti-FLAG, Sigma, 1:2000); IkB-a (C-15, Santa Cruz, 1:500); IKK-a (rabbit antihuman IKK-a, Sigma, 1:1000); IKK-b (monoclonal 62AT216, Abgent Inc., San Diego, CA, USA; 1:500); phospho-IKK-a/b (sc-21661, Santa Cruz, 1:500); p110a (sc-8010, Santa Cruz, 1:300); MKK3 (no. 9232, rabbit polyclonal, Cell Signaling Technology, 1:1000); MKK6 (no. 9264, rabbit polyclonal, Cell Signaling Technology, 1:1000); Raf1 (C-20, Santa Cruz, 1:1000 or no. 1560-1, Epitomics Inc., Burlingame, CA, USA, 1:500); phospho-Raf1 (pS259, Epitomics, 1:500); RalA (mouse monoclonal, BD Transduction Laboratories, San Diego, CA, USA, 1:100 or R23520, rabbit polyclonal, 1:400, Signal Transduction Laboratories, Lexington, KY, USA); RalGDS (C-19, Santa Cruz, 1:500); Ras (R4025, Sigma, 1:1000); and actin (goat polyclonal, Santa Cruz, 1:1000).
Immunofluorescence microscopy to detect p65 (RelA) subcellular translocation After transfection and treatment with SF (see text and figure legends), DU-145 cells cultured on glass coverslips in six-well plastic dishes were fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA, USA) in PBS for 10 min at 251C. The cells were then permeabilized using Tween-20 (in PBS) for 10 min at 251C; incubated in PBS containing 1% BSA for 1 h at 251C to block nonspecific staining; and incubated overnight at 41C with rabbit antihuman p65 polyclonal antibody (1:100 dilution) (Santa Cruz). The cells were then washed and incubated with Cy5-conjugated goat anti-rabbit IgG antibody (Sigma) (1:100 in blocking buffer) for 1 h at 371C and washed five times with PBS. The coverslips were mounted on glass slides with Mowiol 4-88 (Hoechst Celanese, Somerville, NJ, USA). A laser with a wavelength of 638 nm was utilized for excitation of Cy5 fluorescence. Fluorescence images were captured with a Nikon Eclipse E800 confocal laser fluorescence microscope with an objective lens ( Â 40) (Diagnostic Instruments, Sterling Heights, MI, USA). The images were collected through the specimens every 3 s in the vertical plane and overlaid to generate focus composite images. The images were exported and displayed images were exported to Adobe Photoshop (Adobe, San Jose, CA, USA).
Statistical analyses
Where appropriate, statistical comparisons were made using the two-tailed Student's t-test.
